news
CVN058 shows promise in Phase Ib schizophrenia cognition study
A single dose of CVN058 was able to normalise brainwaves being used as a biomarker for cognitive impairment associated with schizophrenia.
List view / Grid view
Schizophrenia
news
EMA recommends eight drugs for approval from April meeting
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
news
MHRA issues Medicine Defect Information about Aripiprazole
The regulatory body has issued guidance based on a complaint that stated a precipitate formed in Aripiprazole 1mg/ml oral solution.
news
MHRA issues alert for missing information on Atrolak XL tablet leaflets
Side effects revealed during post-marketing experience are not listed on Atrolak XL prolonged-release tablet patient information leaflets, announces the MHRA.
news
Heritage announces product recall after sterility test failure
Heritage has recalled two of its injectable treatments after microbial growths were found.
news
FDA approves Aristada Inito for the initiation of Aristada for schizophrenia
Novel regimen enables physicians to fully dose up to two months of Aristada treatment on day one...
news
Study examines antipsychotic medication for children with autism
Children with intellectual difficulty or autism are more likely to be given antipsychotic medication from a younger age than those without intellectual disability...
news
Novel methodology increases resolution in oligodendrocyte proteomics
Brazilian researchers combine mass spectrometry, 2-D liquid chromatography and ion mobility to identify over 10,000 proteins in brain cells possibly involved in schizophrenia.
news
Sodium benzoate enhances schizophrenia treatment
A randomised, double-blind, placebo-controlled trial has found that sodium benzoate improves symptoms in clozapine-resistant schizophrenia...
news
FDA approves pill that tracks if patients have ingested their medication
The FDA has approved the first drug in the U.S. with a digital ingestion tracking system that records that the medication was taken...
news
FDA approves Vraylar in the maintenance treatment of schizophrenia
The FDA has approved the supplemental New Drug Application for Vraylarfor the maintenance treatment of adults with schizophrenia...
news
Gene breakthrough on lithium treatment for bipolar disorder
Genes linked to schizophrenia in psychiatric patients suffering from bipolar disorder are the reason why such patients don't respond to the drug lithium...
news
Study shows contrasting cognitive effects of psychiatric drugs
A long-term study has found that low cumulative exposure to benzodiazepine does not affect cognition in schizophrenia...
news
Braeburn achieves endpoints in implant study to treat Schizophrenia
8 May 2017 | By Niamh Marriott, Junior Editor
Braeburn Pharmaceuticals’ 6-month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed with schizophrenia...
news
Alexza granted FDA approval of Adasuve sNDA to treat schizophrenia
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Administration of Adasuve results in rapid absorption of loxapine, with a maximum plasma concentration achieved in approximately 2 minutes...
